208 related articles for article (PubMed ID: 9706046)
1. A comparison of the bioconversion rates and the Caco-2 cell permeation characteristics of coumarin-based cyclic prodrugs and methylester-based linear prodrugs of RGD peptidomimetics.
Camenisch GP; Wang W; Wang B; Borchardt RT
Pharm Res; 1998 Aug; 15(8):1174-81. PubMed ID: 9706046
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of novel coumarin-based esterase-sensitive cyclic prodrugs of peptidomimetic RGD analogs with improved membrane permeability.
Wang B; Wang W; Camenisch GP; Elmo J; Zhang H; Borchardt RT
Chem Pharm Bull (Tokyo); 1999 Jan; 47(1):90-5. PubMed ID: 9987829
[TBL] [Abstract][Full Text] [Related]
3. Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: evaluation of the chemical and enzymatic stability as well as their transport properties across Caco-2 cell monolayers.
Bak A; Gudmundsson OS; Friis GJ; Siahaan TJ; Borchardt RT
Pharm Res; 1999 Jan; 16(1):24-9. PubMed ID: 9950274
[TBL] [Abstract][Full Text] [Related]
4. Esterase-sensitive cyclic prodrugs of peptides: evaluation of an acyloxyalkoxy promoiety in a model hexapeptide.
Pauletti GM; Gangwar S; Okumu FW; Siahaan TJ; Stella VJ; Borchardt RT
Pharm Res; 1996 Nov; 13(11):1615-23. PubMed ID: 8956324
[TBL] [Abstract][Full Text] [Related]
5. Phenylpropionic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeation.
Gudmundsson OS; Nimkar K; Gangwar S; Siahaan T; Borchardt RT
Pharm Res; 1999 Jan; 16(1):16-23. PubMed ID: 9950273
[TBL] [Abstract][Full Text] [Related]
6. Coumarinic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeability.
Gudmundsson OS; Pauletti GM; Wang W; Shan D; Zhang H; Wang B; Borchardt RT
Pharm Res; 1999 Jan; 16(1):7-15. PubMed ID: 9950272
[TBL] [Abstract][Full Text] [Related]
7. A modified coumarinic acid-based cyclic prodrug of an opioid peptide: its enzymatic and chemical stability and cell permeation characteristics.
Ouyang H; Tang F; Siahaan TJ; Borchardt RT
Pharm Res; 2002 Jun; 19(6):794-801. PubMed ID: 12134949
[TBL] [Abstract][Full Text] [Related]
8. Esterase-sensitive cyclic prodrugs of peptides: evaluation of a phenylpropionic acid promoiety in a model hexapeptide.
Pauletti GM; Gangwar S; Wang B; Borchardt RT
Pharm Res; 1997 Jan; 14(1):11-7. PubMed ID: 9034215
[TBL] [Abstract][Full Text] [Related]
9. Syntheses of cyclic prodrugs of RGD peptidomimetics with various macrocyclic ring sizes: evaluation of physicochemical, transport and antithrombic properties.
He HT; Xu CR; Song X; Siahaan TJ
J Pept Res; 2003 Jun; 61(6):331-42. PubMed ID: 12753380
[TBL] [Abstract][Full Text] [Related]
10. A coumarin-based prodrug strategy to improve the oral absorption of RGD peptidomimetics.
Wang W; Camenisch G; Sane DC; Zhang H; Hugger E; Wheeler GL; Borchardt RT; Wang B
J Control Release; 2000 Mar; 65(1-2):245-51. PubMed ID: 10699284
[TBL] [Abstract][Full Text] [Related]
11. Bifunctional peptidomimetic prodrugs of didanosine for improved intestinal permeability and enhanced acidic stability: synthesis, transepithelial transport, chemical stability and pharmacokinetics.
Yan Z; Sun J; Chang Y; Liu Y; Fu Q; Xu Y; Sun Y; Pu X; Zhang Y; Jing Y; Yin S; Zhu M; Wang Y; He Z
Mol Pharm; 2011 Apr; 8(2):319-29. PubMed ID: 21280612
[TBL] [Abstract][Full Text] [Related]
12. Transport characteristics of peptidomimetics. Effect of the pyrrolinone bioisostere on transport across Caco-2 cell monolayers.
Sudoh M; Pauletti GM; Yao W; Moser W; Yokoyama A; Pasternak A; Sprengeler PA; Smith AB; Hirschmann R; Borchardt RT
Pharm Res; 1998 May; 15(5):719-25. PubMed ID: 9619780
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of the coumarinic acid-based cyclic prodrug of the opioid peptide DADLE.
Tang F; Borchardt RT
Pharm Res; 2002 Jun; 19(6):787-93. PubMed ID: 12134948
[TBL] [Abstract][Full Text] [Related]
14. Enhancing Oral Bioavailability of Cyclic RGD Hexa-peptides by the Lipophilic Prodrug Charge Masking Approach: Redirection of Peptide Intestinal Permeability from a Paracellular to Transcellular Pathway.
Schumacher-Klinger A; Fanous J; Merzbach S; Weinmüller M; Reichart F; Räder AFB; Gitlin-Domagalska A; Gilon C; Kessler H; Hoffman A
Mol Pharm; 2018 Aug; 15(8):3468-3477. PubMed ID: 29976060
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of a novel cyclic prodrug of RGD peptidomimetic to improve its cell membrane permeation.
Song X; Xu CR; He HT; Siahaan TJ
Bioorg Chem; 2002 Aug; 30(4):285-301. PubMed ID: 12392707
[TBL] [Abstract][Full Text] [Related]
16. Prodrug approach for alphaIIbbeta3-peptidomimetic antagonists to enhance their transport in monolayers of a human intestinal cell line (Caco-2): comparison of in vitro and in vivo data.
Kamm W; Raddatz P; Gante J; Kissel T
Pharm Res; 1999 Oct; 16(10):1527-33. PubMed ID: 10554093
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE.
Tang F; Borchardt RT
Pharm Res; 2002 Jun; 19(6):780-6. PubMed ID: 12134947
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and conformational analysis of a coumarinic acid-based cyclic prodrug of an opioid peptide with modified sensitivity to esterase-catalyzed bioconversion.
Ouyang H; Vander Velde DG; Borchardt RT; Siahaan TJ
J Pept Res; 2002 Apr; 59(4):183-95. PubMed ID: 11972752
[TBL] [Abstract][Full Text] [Related]
19. An in vitro system for prediction of oral absorption of relatively water-soluble drugs and ester prodrugs.
He X; Sugawara M; Kobayashi M; Takekuma Y; Miyazaki K
Int J Pharm; 2003 Sep; 263(1-2):35-44. PubMed ID: 12954178
[TBL] [Abstract][Full Text] [Related]
20. Optimizing oral absorption of peptides using prodrug strategies.
Borchardt RT
J Control Release; 1999 Nov; 62(1-2):231-8. PubMed ID: 10518655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
